Business Context and Reporting Period
Company: Mangoceuticals, Inc. (MGRX)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2024
Business Overview: Mangoceuticals operates a telehealth platform connecting consumers to licensed healthcare professionals for men's wellness products, including compounded treatments for erectile dysfunction (Mango ED), hair loss (Grow), hormone balance (Mojo), and weight management (Slim). The company also distributes FDA-approved oral testosterone (Prime). Operations rely heavily on a related-party pharmacy, Epiq Scripts, LLC (52% owned by CEO Jacob D. Cohen), for compounding and fulfillment.
Key Financial Metrics
| Metric | 2024 | 2023 |
|---|---|---|
| Revenue | $615,873 | $731,493 |
| Gross Profit | $379,964 | $431,501 |
| Net Loss | $(8,707,226) | $(9,212,417) |
| Accumulated Deficit | $(20,806,595) | $(11,228,173) |
| Cash and Equivalents | $58,653 | $739,006 |
| Working Capital | $(1,349,868) | $624,324 |
| Total Assets | $15,370,511 | $1,050,793 |
| Total Liabilities | $1,425,463 | $276,039 |
Note: The significant increase in Total Assets is primarily due to the acquisition of intangible assets (patents) valued at approximately $15.9 million, funded largely by the issuance of Series C Preferred Stock.
Material Changes vs. Prior Period
- Revenue Decline: Revenue decreased by approximately 16% year-over-year, attributed to issues during the transition and migration from the original telemedicine platform to a new telehealth platform.
- Expense Reduction: Total operating expenses decreased by approximately $1.3 million, driven by reduced advertising and marketing spend ($1.48M vs $2.10M) and lower investor relations costs ($0.45M vs $1.10M), partially offset by increased salaries and stock-based compensation.
- Reverse Stock Split: A 1-for-15 reverse stock split was effected on October 16, 2024, to regain compliance with Nasdaq minimum bid price requirements. All share data in this report is retroactively adjusted.
- Asset Acquisition: The company acquired patent portfolios from Intramont Technologies (respiratory illness prevention) and Greenfield Investments (mushroom-derived nutraceuticals), resulting in a significant increase in intangible assets.
- Corporate Restructuring: Substantially all assets were contributed to a new wholly-owned subsidiary, Mango & Peaches Corp., in December 2024 to segregate operations and liabilities.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Guidance
Management states that current capital resources are not sufficient to fund operations for the next 12 months. The company anticipates a need for additional funding through equity or debt offerings, which may result in significant dilution. The company is evaluating strategic alternatives, including mergers or acquisitions.
Material Risks
- Going Concern: The independent auditor has included an explanatory paragraph regarding substantial doubt about the company's ability to continue as a going concern due to recurring losses and negative cash flows.
- Regulatory & FDA: The company's core "Compounded Products" are not FDA-approved. The company relies on Section 503A exemptions, which carry risks of regulatory enforcement if the FDA determines the products are "essentially copies" of approved drugs or if safety issues arise.
- Related Party Dependence: The company relies exclusively on Epiq Scripts, LLC (owned by the CEO) for pharmacy services. This creates significant conflict of interest risks and operational dependency.
- Legal Proceedings: Eli Lilly and Company filed a lawsuit in October 2024 alleging false advertising regarding the company's "TRIM" product (oral dissolvable tirzepatide). The product has been removed from the website, and the company intends to defend the matter.
- Control Concentration: Following the Mango & Peaches restructuring, CEO Jacob D. Cohen is positioned to obtain majority voting control (approx. 75.5%) of the subsidiary holding the company's assets, potentially limiting other shareholders' influence.
Investor Verification Checklist
- Liquidity Runway: Verify the status of the company's cash position ($58,653) and the timeline for securing the necessary additional funding to avoid insolvency.
- Related Party Transactions: Scrutinize the terms of the Master Services Agreement with Epiq Scripts and the recent assignment of these agreements to the Mango & Peaches subsidiary to ensure arm's-length pricing and terms.
- Legal Exposure: Monitor the status of the Eli Lilly litigation and the potential for injunctions or damages that could halt operations.
- Capital Structure: Review the terms of the Series B and Series C Convertible Preferred Stock, including liquidation preferences and conversion prices, which could lead to significant dilution of common shareholders.
- Regulatory Compliance: Assess the risk of FDA action against the compounded products, given the lack of clinical trials for the specific sublingual formulations used.